Jun Ma
Jun Ma is the world's leading nasopharyngeal carcinoma trialist, whose randomised studies define induction chemotherapy and immunotherapy for the disease.
Jun Ma's trials at SYSUCC established gemcitabine-cisplatin induction chemotherapy, defined the role of EBV DNA in risk stratification, and, with colleagues, tested PD-1 blockade in nasopharyngeal carcinoma, shaping international guidelines.
| Title | Journal | Year |
|---|---|---|
| Gemcitabine and cisplatin induction chemotherapy in nasopharyngeal carcinoma | NEJM | 2019 |
Pages like this
not linked directly; found by shared links- PersonMu-Sheng Zeng
Shares Sun Yat-sen University Cancer Center, Head and neck squamous cell carcinoma.
- IdeaBlood EBV DNA screening for nasopharyngeal cancer across southern China and Southeast Asia
Shares Sun Yat-sen University Cancer Center, Head and neck squamous cell carcinoma.
- IdeaPhotobiomodulation and a taste and swallowing programme for mouth and throat toxicity
Shares IMRT / IGRT (modern external beam), Head and neck squamous cell carcinoma.
- TrialTrilynX
Shares IMRT / IGRT (modern external beam), Head and neck squamous cell carcinoma.
- TrialJAVELIN Head and Neck 100
Shares IMRT / IGRT (modern external beam), Head and neck squamous cell carcinoma.
- PersonWenfeng Fang
Shares Sun Yat-sen University Cancer Center, Head and neck squamous cell carcinoma.
- ProductToripalimab
- InstitutionUniversity of Malaya Medical Centre
Shares IMRT / IGRT (modern external beam), Head and neck squamous cell carcinoma.